

**Research Compliance Activity and Turn-Around-Time (TAT) Summary Report**  
 Fiscal Year 2019 (7/1/2018 to 6/30/2019)

*TAT calculated from submission date to date of approval. TAT not calculated for continuing reviews.*

<b>Institutional Biosafety Committee (IBC) - Bloomington</b>										
	Q1 TAT		Q2 TAT		Q3 TAT		Q4 TAT		FY-END TAT	
	Mean	Median	Mean	Median	Mean	Median	Mean	Median	Mean	Median
<b>Full Board</b>	<b>Full Board</b>									
New Studies - Full Board (to review)	17.0	15.5								
New Studies - Full Board (to approval)	26.8	25.0								
<b>Exempt</b>	<b>Exempt</b>									
New Studies - Exempt (to determination)	23.8	22.5								
<b>Amendments</b>	<b>Amendments</b>									
Amendments - Minor	4.0	1.0								
Amendments - Major	52.5	52.5								

\*Note: TAT includes a "pre-review" time frame occurring prior to full committee meeting.

Area Activities/Throughput (T)	Q1 (Jul-Sep)			Q2 (Oct-Dec)			Q3 (Jan-Mar)			Q4 (Apr-Jun)		
	Received	Completed	Throughput/ % Backlogged									
New Studies - Full Board	3	4	1									
New Studies - Exempt	7	6	-1 (14.3%)									
Amendments - Minor	52	51	-1 (1.9%)									
Amendments - Major	0	1	1									
Continuing Reviews	31	28	-3 (9.7%)									
<b>TOTAL</b>	<b>93</b>	<b>90</b>	<b>-3 (3.2%)</b>	<b>0</b>	<b>0</b>		<b>0</b>	<b>0</b>		<b>0</b>	<b>0</b>	

Area Training Activities	Q1 (Jul-Sep)	Q2 (Oct-Dec)	Q3 (Jan-Mar)	Q4 (Apr-Jun)	FY TOTALS
Presentations (# of events)	0				0

Reportable Events/Activities	Q1 (Jul-Sep)	Q2 (Oct-Dec)	Q3 (Jan-Mar)	Q4 (Apr-Jun)	FY TOTALS
Immediate OBA Report	0				0
30 Day OBA Report	2				2
Lab Accident/Injury/Exposure	0				0

Reporting Agency: NIH Office of Biotechnology Activities (OBA)